Few new drugs deserve expedited regulatory treatment

J Manag Care Spec Pharm. 2021 May;27(5):685-688. doi: 10.18553/jmcp.2021.27.5.685.


DISCLOSURES: This commentary is based on work by the author that was supported by Arnold Ventures and the Harvard-MIT Center for Regulatory Science. The funders had no role in the writing of this commentary, or the decision to submit for publication. The author has nothing else to disclose.

MeSH terms

  • Drug Approval / organization & administration*
  • Government Regulation*
  • Humans
  • Time Factors
  • United States
  • United States Food and Drug Administration